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Original Article

Pablo E. Pergola,1 Carole L. White,2 Jeff M. Szychowski,3 Robert Talbert,4 Oscar del Brutto,5
Mar Castellanos,6 John W. Graves,7 Gonzalo Matamala,8 Edwin Javier Pretell,9 Jerry Yee,10
Rosario Rebello,11 Yu Zhang,3 and Oscar R. Benavente;12 for the SPS3 Investigators
background
Lowering blood pressure (BP) after stroke remains a challenge, even
in the context of clinical trials. The Secondary Prevention of Small
Subcortical Strokes (SPS3) BP protocol, BP management during the
study, and achieved BPs are described here.

1.8 ± 1.4 (higher group) by the end-study visit. It took an average of
6 months for patients to reach their SBP target, sustained to the last follow-up. Black participants had the highest proportion of SBP ≥150 mm
Hg at both study entry (40%) and end-study visit (17%), as compared
with whites (9%) and Hispanics (11%).

methods
Patients with recent symptomatic lacunar stroke were randomized to
1 of 2 levels of systolic BP (SBP) targets: lower: <130 mm Hg, or higher:
130–149 mm Hg. SBP management over the course of the trial was
examined by race/ethnicity and other baseline conditions.

conclusions
These results show that it is possible to safely lower BP even to a SBP
goal <130 mm Hg in a variety of patients and settings, including private
and academic centers in multiple countries. This provides further support for protocol-driven care in lowering BP and consequently reducing
the burden of stroke.

results
Mean SBP decreased for both groups from baseline to the last followup, from 142.4 to 126.7 mm Hg for the lower SBP target group and from
143.6 to 137.4 mm Hg for the higher SBP target group. At baseline, participants in both groups used an average of 1.7 ± 1.2 antihypertensive
medications, which increased to a mean of 2.4 ± 1.4 (lower group) and

Keywords: achieved blood pressures; blood pressure; blood pressure
management; hypertension; ischemic stroke; lacunar stroke; stroke
prevention.
doi:10.1093/ajh/hpu027

Hypertension is the most important risk factor for stroke with
data from both randomized trials and meta-analyses supporting the importance of blood pressure (BP) lowering for
secondary stroke prevention.1–5 Despite the evidence, studies
continue to report inadequate BP control in those with prior
stroke.6–9 The challenges of lowering BP are not unique to
clinical practice, and even within the context of BP clinical trials, achieving goal systolic BP (SBP) has proven difficult.10–12

The Secondary Prevention of Small Subcortical Strokes
(SPS3) trial13 was conducted in 81 sites across 8 countries between May 2003 and April 2012. The primary
objective was to identify effective strategies for secondary stroke prevention, including lowering SBP to a target
of <130 mm Hg. The purpose of this report is to provide
detailed information on the implementation of the SPS3
BP protocol, including strategies used to enhance fidelity
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Achieved Blood Pressures in the Secondary Prevention of
Small Subcortical Strokes (SPS3) Study: Challenges and
Lessons Learned

Achieved Blood Pressures in SPS3

to the protocol, achieved BPs, and factors associated with
failure to achieve SBP goal.
METHODS

SPS3 BP protocol

Research personnel were trained on a standardized protocol for BP measurement16,17 and provided with a validated
automated electronic device.18 Three measurements, separated by 2 minutes, were averaged. Sites were asked to record
and use the first 3 measurements to avoid the bias of selecting 3 out of multiple measurements. Printers were installed
on a selection of BP machines to ensure that printed values
matched values on case report forms and that only the initial
3 measurements were used.
After randomization, all patients were seen monthly for
3 months and thereafter on a quarterly basis for management of SBP to the assigned target. The average of the 3
in-clinic measurements was used to determine whether the
patient was within target; those who were not continued to
be seen at least monthly for BP management until their SBP
was within the assigned target for 2 consecutive visits, the
SPS3 definition for achieving SBP target (Figure 1). To assess
for orthostatic hypotension, sitting BP was compared with
BP after standing for 2 minutes.
BP control was overseen at each clinical site by a physician with expertise in BP management. Patients were evaluated for secondary causes of hypertension and treatment
tailored to address any secondary causes at baseline and
through-out the study. Investigators were encouraged to use
the most effective medications to lower BP. An algorithm
was developed and distributed to the sites (Supplementary
Appendix S1). This nonprotocol-mandated algorithm advocated titration of dose, as well as addition of agents, using
a stepwise approach, monitoring carefully for side effects.16
Diastolic BP was considered as needed for safety reasons but
not managed per protocol. By protocol, patients assigned to
the higher target (130–149 mmHg) with SBP below target
and on BP-lowering medications had them discontinued
or their dose reduced to bring SBP into target, unless prescribed for reasons other than BP control. Participants with
SBP below target in the higher group and on no BP-lowering

Figure 1. Follow-up algorithm. Abbreviation: SBP, systolic blood pressure.

American Journal of Hypertension 27(8) August 2014

1053

Downloaded from https://academic.oup.com/ajh/article/27/8/1052/2743252 by Henry Ford Hospital - Sladen Library user on 22 June 2022

The rationale and design of the SPS3 trial are presented
in detail elsewhere.13,14 In brief, eligible patients were aged
≥30 years, with a clinical lacunar stroke syndrome15 within
6 months before enrollment with confirmation by magnetic
resonance imaging and no surgically amenable ipsilateral
carotid artery disease or major-risk cardioembolic sources.
They were randomized to 1 of 2 levels of SBP control, a lower
target (<130 mm Hg) and a higher target (130–149 mm Hg),
and simultaneously to an antiplatelet regimen. Both normotensive and hypertensive patients were eligible, with status
determined by average BP from 2 prerandomization visits.
There was no washout period for antihypertensive medications. The SPS3 study was approved by the institutional
review boards of all participating centers, and all patients
provided written informed consent.

medications were followed quarterly, and if their SBP
increased, they were managed into their assigned target.
Antihypertensive medications were provided free of charge
to participants, as deemed appropriate by the local site team.
Medications available in the SPS3 formulary included at least
1 drug from most classes (Supplementary Appendix S2) and
relied heavily on the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) formulary because of its proven effectiveness.19 Medications were
also selected based on their half-life to enhance adherence
(daily dosing preferred) and their availability through the
Cooperative Studies Program Clinical Research Coordinating
Center, Department of Veterans Affairs. The SPS3 formulary was not used in several countries because of the difficulties in shipping medications and the availability of local
government-subsidized medication plans. There were several
situations where ongoing monitoring of current evidence
suggested minor tailoring of the formulary to ensure that best
practice was provided to all participants.20,21
Patients were designated “inactive” in the BP protocol if
they or their primary care physicians refused to have their
BP managed to their assigned target by SPS3 investigators.
Patients were designated “failure to achieve assigned target”
if for medical reasons their BP could not be managed into
the assigned target or for patients who suffered intolerable
side-effects, despite trying multiple agents. All participants
were followed to a common end-study date, irrespective of
active/inactive or failure to achieve assigned target status.
The Steering Committee and the Blood Pressure Steering
Sub-Committee provided guidance and oversight to ensure
that the BP protocol was implemented in a standardized
manner across sites. They were charged with internal monitoring of patient safety and keeping current with publications in the field to ensure that the BP protocol remained
ethical and safe.
Adherence to the BP protocol was supported through continuous analysis and feedback to the clinical sites regarding
protocol deviations and safety concerns.18 Weekly reports to
sites showed the percentage of patients by site within their SBP
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target, and quarterly reports provided detailed information
about BP management, and for safety, participants with very
high or low SBP and heart rates. In addition to regular conference calls between the Coordinating Center and the clinical
sites, sites with poor performance in managing patients into
their assigned targets were identified for additional discussion
and recommendations for challenging patient management.

Participant characteristics were compared between the
lower and higher SBP target groups using analysis of variance for quantitative measures, χ2 tests of association for
nominal categorical measures, and χ2 tests of trend for ordinal categorical measures. Means ± SDs and frequencies (%)
are presented. To examine aspects of implementation of
the BP protocol by trial personnel, counts and percentages
of participants for whom <25%, 25%–49%, 50%–75%, and
>75% of all study visits were always active, ever inactive, and
failure to achieve assigned target are presented by BP target
group and compared with the Cochran–Mantel–Haenszel
test. There were a small percentage of normotensive subjects
in each treatment arm, and they were included in all analyses. SAS versions 9.2 and 9.3 (SAS Institute, Cary, NC) were
used for all statistical analyses.
RESULTS

The average age of the 3,020 participants was 63 ± 11 years,
63% were men, and 51% were white, 30% were Hispanic, and
16% were black. The majority were from the United States
(56%), followed by Latin America (23%), Spain (12%), and
Canada (9%). Hypertension, hyperlipidemia, and diabetes
were the most prevalent vascular risk factors, present in
75%, 49%, and 37% of subjects, respectively. The majority
(67%) demonstrated good functional recovery from stroke
as evidenced by a modified Rankin Score22 of 0 or 1. Patients
were followed for a mean of 3.7 ± 2.0 years.
The mean SBP decreased for both groups from baseline
to the last follow-up, from 142.4 to 126.7 mm Hg (lower target group) and from 143.6 to 137.4 mm Hg (higher target
group) (Table 1). Baseline BPs were similar by sex, as were
responses to the BP protocol. The percentage of patients
with controlled hypertension (SBP < 140 mm Hg) was
similar for both groups at baseline (approximately 47%); by
end-study this increased to 85.1% in the lower SBP target
group compared with 57.7% in the higher SBP target group.
Approximately 75% of participants were always active in the
BP protocol, whereas approximately 22% of participants were
designated as inactive at least once and 3%–4% of participants were designated as failure to achieve assigned target,
with no differences by SBP target group. The mean number
of follow-up and BP visits over the course of the study was
the same regardless of SBP target (21.3 ± 11.6 vs. 21.6 ± 12.2,
lower and higher groups respectively; P > 0.05), decreasing
from an average of 7 visits the first year to approximately 5
visits per year in subsequent years. The majority of participants reported adherence as “excellent” or “good” at >75% of
their quarterly visits. There was no difference by treatment
1054 American Journal of Hypertension 27(8) August 2014

Discussion

This article examined SBP management in the 3,020
participants of the SPS3 trial over the course of the study.
The main finding is that SBP can be safely lowered and the
decrease sustained over time in most patients with established cerebrovascular disease. There were no differences
by treatment group in cardiovascular events or adverse
events potentially related to lowering SBP.23 These results
also suggest the importance of aiming low to achieve good
control. Although more than one-third of participants had
SBP ≥150 mm Hg at study entry, the proportion with SBP
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Data analysis

group in symptoms possibly related to BP management.
Participants who were in target at >75% of study visits were
more likely to be always active (87.9% and 83.7% of those
always active in lower and higher groups, respectively) compared with being ever inactive (12.1% and 15.4% in lower
and higher groups, respectively) or with failure to achieve
assigned target (0% and 0.9% in lower and higher groups,
respectively; P < 0.0001) (Table 2).
Figures 2 and 3 show the percentage of participants with
SBP in target (group percentage and does not necessarily
include the same individuals at each point in time) over the
course of the study. For the lower SBP target group, the percentage within their assigned target increased during the initial 3–6 months, with continued improvement over the first
2 years of the study. The largest increase in the higher group
was in the initial 6 months, and thereafter there was little
change in percentage in target.
Participants in both groups used an average of 1.7 ± 1.2
antihypertensive medications at baseline, which increased
to a mean of 2.4 ± 1.4 in the lower SBP target group and
1.8 ± 1.4 in the higher SBP target group by the end-study visit
(Table 3). As expected, participants in the lower group used
more medications in all classes than the higher group. After
year 1, percentages were relatively stable for both groups,
with small fluctuations.
Examination of the achieved SBPs by race/ethnicity
(Table 4) shows an increase in the percentage in target from
baseline to end-study visit for both groups. This pattern was
the same regardless of race/ethnicity. Although the percentage with SBP ≥150 mm Hg in the lower group was similar for
Hispanics and blacks at baseline (35.9% and 34.9%, respectively), this decreased by end-study visit to 5.3% in Hispanics
compared with 13.3% in blacks. Black participants also had
the highest proportion of SBP ≥150 mm Hg in the higher
group at end-study visit (21.1%), as compared with whites
(11.8%) and Hispanics (14.8%). The higher SBP readings
for black participants were despite a similar mean number
of BP visits compared with white and Hispanic participants.
Although blacks were prescribed, on average, a higher mean
number of medications throughout the study (Figure 4),
including higher percentages of diuretics and calcium-channel blockers compared with whites and Hispanics (data not
shown), the percentage increase in medications between
baseline and the end of the study in the lower SBP target
group was lower for black participants compared with white
and Hispanic participants.

Achieved Blood Pressures in SPS3
Table 1. Implementation of blood pressure protocol by treatment group

Variable

Lower SBP target

Higher SBP target

(<130 mm Hg) (n = 1,501)

(130–149 mm Hg) (n = 1,519)

142.4 ± 18.5

143.6 ± 19.1

Mean SBP ± SD at last follow-up**

126.7 ± 16.5

137.4 ± 16.2

Mean SBP ± SD across quarterly follow-ups
(excluding initial 6 months)**

125.1 ± 14.7

137.1 ± 14.4

No. (%) in target at last follow-up

1,034 (69.6)

855 (56.9)

Mean DBP ± SD at baseline*

77.6 ± 10.4

79.0 ± 10.8

Mean DBP ± SD at last follow-up**

69.1 ± 10.4

74.8 ± 10.9

Mean DBP ± SD across quarterly follow-ups
(excluding initial 6 months)**

68.5 ± 9.9

75.0 ± 10.3

SBP <140 mm Hg, no. (%)
 Baseline

722 (48.1)

699 (46.0)

 Year 1

1,120 (84.1)

776 (56.9)

 End of study

1,100 (85.1)

754 (57.7)

 Always active

1,147 (76.4)

1,126 (74.1)

 Ever inactive

304 (20.3)

331 (21.8)

Study Status, no. (%)

 Ever failure to achieve assigned target

50 (3.3)

Mean number of BP checks ± SD

62 (4.1)

21.3 ± 11.6

21.6 ± 12.2

1,303 (90.7)

1,248 (92.5)

 Unsteadiness when standing

375 (25)

355 (24)

 Blurred vision when standing

85 (6)

103 (7)

 Dizziness when standing

324 (22)

304 (20)

 Light-headedness when standing

222 (15)

236 (16)

21 (0.2)

24 (0.2)

Antihypertensive medication adherence excellent or
good at >75% of quarterly visits, no. (%)
Side-effects possibly related to blood pressure
management, no. (%)

 Palpitations when standing

Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
* Difference between higher and lower groups is significant at P < 0.001.
** Difference between higher and lower groups is significant at P < 0.0001.

Table 2.

Percentage of quarterly visits with systolic blood pressure (SBP) in target by SBP group and by study status
Lower SBP target (<130 mm Hg) (n = 1,471)a,*

Variable

Overall

Higher SBP target (130–149 mm Hg) (n = 1,479)a,*

Always active

Ever inactive

Ever FAAT

(n = 1,136)

(n = 286)

(n = 49)

Overall

Always active

Ever inactive

Ever FAAT

(n = 1,114)

(n = 303)

(n = 62)

≤25%, no. (%)

126 (8.6)

44 (3.9)

54 (18.9)

28 (57.1)

150 (10.1)

84 (7.5)

43 (14.2)

23 (37.1)

>25%–50%, no. (%)

140 (9.5)

77 (6.8)

47 (16.4)

16 (32.7)

288 (19.5)

182 (16.3)

88 (29.0)

18 (29.0)

>50%–75%, no. (%)

447 (30.4)

349 (30.7)

93 (32.5)

5 (10.2)

600 (40.6)

479 (43.0)

104 (34.3)

17 (27.4)

>75%, no. (%)

758 (51.5)

666 (58.6)

92 (32.2)

441 (29.8)

369 (33.1)

68 (22.4)

4 (6.5)

Abbreviation: FAAT, failure to achieve assigned target.
There were 37 subjects who had only a baseline visit (22 subjects in the lower SBP group and 15 in the higher SBP group) and 33 participants who did not have valid SBP measurements at their quarterly follow-ups (17 in the higher group and 15 in the lower group).
*P < 0.0001
a

American Journal of Hypertension 27(8) August 2014

1055

Downloaded from https://academic.oup.com/ajh/article/27/8/1052/2743252 by Henry Ford Hospital - Sladen Library user on 22 June 2022

Mean SBP ± SD at baseline
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Figure 3. Percentage of patients with systolic blood pressure (SBP) within target (130–149 mm Hg), above target, and below target across the study in
the higher SBP target group. Note that the figure includes the 10.3% who were classified as normotensive at baseline.

≥150 mmHg was 50% less in the lower SBP target group
(7%) compared with the higher SBP target group (15%).
Although not a goal for the SPS3 study, the percentage
with SBP <140 mm Hg was 85% in the lower group and
only 58% in the higher group by end-study visit. Although
1056 American Journal of Hypertension 27(8) August 2014

investigators could aim for SBP <140 mm Hg in the higher
group (130–149 mmHg), it appears that the intensive effort
required to reduce SBP to <130 mm Hg in the lower SBP target group was important for the higher percentage of control
in this group. The implication for practice is that to achieve a
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Figure 2. Percentage of patients with systolic blood pressure (SBP) within target (<130 mm Hg) and above target across the study in the lower SBP
target group. Note that the figure includes the 10.3% who were classified as normotensive at baseline.

Achieved Blood Pressures in SPS3
Table 3.

Antihypertensive medications across study follow-up
Lower SBP target (<130 mm Hg)

Higher SBP target (130–149 mm Hg
End of

End of

Baseline

Year 1

Year 2

Year 3

study

Baseline

Year 1

Year 2

Year 3

study

Mean number ± SD
of medications

1.7 ± 1.2

2.4 ± 1.3

2.5 ± 1.3

2.5 ± 1.3

2.4 ± 1.4

1.7 ± 1.2

1.8 ± 1.4

1.8 ± 1.4

1.8 ± 1.4

1.8 ± 1.4

Diuretic, %

35.7

65.6

68.7

70.8

64.3

36.8

48.1

48.7

51.2

45.9

Beta-blocker, %

25.6

30.7

33.5

34.9

34.9

24.1

25.0

25.4

25.8

28.3

Calcium-channel
blocker, %

25.8

43.1

47.5

45.5

43.2

25.6

29.8

28.8

28.0

29.3

ACEi, %

53.3

52.0

51.3

49.6

47.5

51.2

40.8

39.7

39.7

38.7

ARB, %

15.3

30.6

32.6

35.0

33.6

16.6

23.5

23.5

23.9

23.9

ACEi or ARB/
diuretic, %

60.8

72.9

74.4

74.1

70.7

59.5

54.5

53.7

53.6

51.8

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood pressure.

Table 4. Baseline and achieved systolic blood pressures by race/ethnicitya
Lower SBP target
<130

130–149

≥150

<130

130–149

≥150

Overall

379 (25.8)

630 (42.9)

458 (31.2)

360 (24.3)

605 (40.9)

514 (34.8)

White

219 (28.1)

346 (44.5)

213 (27.4)

199 (26.2)

333 (43.8)

228 (30.0)

Hispanic

110 (24.6)

177 (39.5)

161 (35.9)

116 (24.8)

180 (38.5)

172 (36.8)

Time period

Baseline SBP,
no. (%)

Year 1 SBP, no.
(%)

End-of-study
SBP, no. (%)

Higher SBP target

Black

50 (20.7)

107 (44.4)

84 (34.9)

45 (17.9)

92 (36.7)

114 (45.4)

Overall

892 (68.6)

326 (25.1)

83 (6.4)

319 (23.9)

816 (61.3)

197 (14.8)

White

458 (67.2)

183 (26.8)

41 (6.0)

186 (27.2)

409 (59.7)

90 (13.1)

Hispanic

303 (73.2)

85 (20.5)

26 (6.3)

95 (21.7)

287 (65.5)

56 (12.8)

Black

131 (63.9)

58 (28.3)

16 (7.8)

38 (18.2)

120 (57.4)

51 (24.4)

Overall

863 (70.4)

279 (22.8)

84 (6.9)

339 (28.0)

697 (57.6)

174 (14.4)

White

438 (69.4)

156 (24.7)

37 (5.9)

177 (29.8)

346 (58.3)

70 (11.8)

Hispanic

312 (78.2)

66 (16.5)

21 (5.3)

114 (27.3)

242 (57.9)

62 (14.8)

Black

113 (57.7)

57 (29.1)

26 (13.3)

48 (24.1)

109 (54.8)

42 (21.1)

Abbreviation: SBP, systolic blood pressure.
a Because of the small numbers and heterogeneity of the group, the table excludes 74 participants who reported their race as American
Indian/Alaskan Native, Asian/Pacific Islander, or Other.

high percentage of patients with SBP <140 mm Hg, it may be
necessary to target SBP management at a lower level, such as
130 mm Hg, rather than focusing on the goal of 140 mm Hg.
In line with the protocol, BP treatment began with randomization, with patients achieving assigned targets, on average, by the 6-month follow-up. Over the remaining mean
3.7 years of follow-up, the initial gains in the percentage in
target were sustained, irrespective of race/ethnicity. An earlier examination of achieved BP control in this cohort with
a subset who had completed 1 year of follow-up showed
that those patients who were in target at 6 months were 2.4
times more likely to be in target at 1 year compared with
the group that had not achieved target.24 The results presented here suggest that this holds true for the duration of

the study. Similarly, ALLHAT reported the largest gains in
percentage in target occurred early in the trial, with continued improvement over time to 65.6% in target at year 5.25
More recently, the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial also showed the biggest gains in
achieving target were in the initial 6 months, sustained over
the course of the trial.26 Taken together, these results underscore the importance of early and intensive BP management.
Examination of baseline BP in this cohort before randomization and SPS3 study interventions demonstrated that
>50% of participants had uncontrolled SBP at approximately 3 months after stroke and almost 20% had baseline
SBP values consistent with stage 2 (≥160 mm Hg) hypertension despite treatment.9 After 1 year of participation in the
American Journal of Hypertension 27(8) August 2014
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trial, however, approximately two-thirds were within their
assigned target. Patients, systems including access to care,
and providers have been proposed as barriers to BP control.
The SPS3 protocol was designed to overcome these barriers
in a way that could be reproducible in clinical practice. The
SPS3 protocol was a bundle that included a focus on accurate
measurement of BP, attention to patient adherence to prescribed treatment at each clinic visit, and timely titration and
medication intensification as needed, with an algorithm to
guide practice. Furthermore, sites were provided with regular feedback about the proportion of patients in target and
comparison with other sites along with conference calls to
the sites to discuss difficult cases. A number of studies have
recommended a protocol-based strategy along with clinical
monitoring and regular clinician feedback for achieving BP
control.27–30 In a cluster randomized controlled trial conducted over a 16-week period in general practice, Godwin
and colleagues29 reported a significant improvement in BP
control at 12 months using a protocol-based strategy for BP
control. Similar to SPS3, there was flexibility with regard to
the combination of medications used for individual patients,
designed to reach their achieved target and to minimize side
effects. An adapted version of the SPS3 protocol has already
shown effectiveness in reducing SBP in another stroke prevention trial.31
The disparity in prevalence and control of hypertension
among black participants reported here is consistent with
previous reports of poorer control in this population.32–34
The ALLHAT study showed a lower hypertension control
rate in black participants after 4 years of follow-up, with
approximately 60% achieving SBP < 140 mmHg in contrast
with 68% in white participants.35 This is despite a standardized rigorous protocol that involved treating participants to
1058 American Journal of Hypertension 27(8) August 2014

a target, similar to SPS3. Although black participants were
taking a higher mean number of medications than whites
or Hispanics at both study entry and across follow-ups, the
lower control rates seen here may suggest that a more intensive medication regimen was needed. Medication use in
Hispanics increased by 0.9 mean medications from baseline
to end-study, and SBP ≥150 mmHg decreased from 36% to
5% in the lower SBP target group. For blacks, the increase
was 0.7 mean medications, and SBP ≥150 mm Hg decreased
from 35% to 13% in the lower SBP target group. Adherence
as measured by missing visits and inactive status was not different for blacks.
A challenging aspect of the trial was managing those
patients in the higher group (130–149 mm Hg) who were
below target. The protocol mandated a reduction of dose or
number of antihypertensive medications for those patients
with SBP <130 mm Hg unless there were clinical contraindications such as non-BP management indications. We saw
small increases in the proportion with SBP <130 mm Hg
between baseline and the end-study visit, regardless of race/
ethnicity. These findings demonstrate the difficulty of delivering an intervention when there may not be equipoise in
the community.
The high rate of controlled hypertension that was achieved
is within the context of a clinical trial. Features that are
common to clinical trials, such as a high level of commitment of the participants and the close follow-up by research
coordinators, may suggest that the control seen here is better than what could be expected in clinical practice. The BP
protocol was designed, however, to be generalizable to clinical practice. It was based on published guidelines,16,17 and
medications used in the trial are those commonly available.
Although medications were made available to participants,
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Figure 4. Mean number of antihypertensive medications over time by race/ethnicity.

Achieved Blood Pressures in SPS3
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